| Citation | Peter Sadler is well known for his research into the chemistry of metals in medicine, a field that was largely unexplored until his research programme began in 1973. He was the first to propose an injectable gold(1) thiolate drug for the treatment of arthritis and he has since continued to study the chemistry of such materials including the new antiarthritic drug, auranofin and has recently extended this, in collaboration with SmithKline, to the anticancer activity of gold(I) diphosphine complexes. His contribution to the chemistry of platinum anticancer drugs has been of major importance. For example, carboplatin, was first crystallized in his laboratory and he has made many contributions to the 15N NMR of such materials and the investigation of their mode of attack. He has made a major contribution to the understanding of the role of bismuth drugs, the function of metallothionein, the design and synthesis of novel paramagnetic compounds for use in magnetic resonance imaging and on the NMR of whole body fluids. |